Drug intelligence / Profile preview

CADI-T3021

Development stage: Preclinical
Lead developer: Bio-Modeling Systems

Overview

CADI-T3021 is a preclinical therapeutic protocol developed by Bio-Modeling Systems (BMSystems) for the treatment of Parkinson's Disease. Discovered using the proprietary CADI (Computer Assisted Deductive Integration) platform, which utilizes augmented intelligence to model complex biological mechanisms, the program targets mitochondrial function to improve cellular energy and mitochondrial performance. The therapeutic is designed to address the underlying mitochondrial dysfunction associated with Parkinson's pathology. As of the latest pipeline updates, CADI-T3021 is in the preclinical development phase, with a proof-of-concept trial being prepared for human subjects.

Targets

Neuraminidase

Beyond the preview

Go deeper on CADI-T3021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CADI-T3021.

Explore the full profile